– USA, OH – Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has appointed John (Jack) P. Kenny as Chief Executive Officer, effective October 9, 2017. This addition to Meridian’s management team is consistent with the succession planning described in our May 10, 2017 press release. Mr. Kenny joins Meridian after a search of several months by a Special Committee of the Board of Directors, working closely with management. Mr. Kenny has also been appointed to Meridian’s Board of Directors effective October 9, 2017.
Concurrent with the hiring of Mr. Kenny, John (Jack) A. Kraeutler, Chief Executive Officer and Chairman of the Board, steps down as CEO and takes the title of Executive Chairman.
Mr. Kenny most recently served as Senior Vice President/General Manager, North America, at Siemens Healthcare. Mr. Kenny led a turnaround of the business to restore sales growth while driving increased profits and revamped the culture to build a sustainable, high-performing commercial organization. He has held executive level roles at Becton Dickinson, Leica Biosystems, and Quest Diagnostics. Mr. Kenny holds a BS, Management Systems, from Kettering University in Flint, Michigan.
Jack Kraeutler commented, “Mr. Kenny has an excellent background and a strong track record in adding value to commercially-oriented businesses. He is a high-energy leader who has the ability to motivate employees and is well-suited to leading Meridian. I believe that Mr. Kenny will fit into the organization seamlessly and will drive Meridian’s next phase of growth. I look forward to working with Mr. Kenny during fiscal 2018 to ensure a smooth transition.”
Mr. Kenny commented, “I am excited to join Meridian Bioscience. I have watched the Company’s progress for many years. The Company’s reputation in the marketplace is strong. Meridian has a strong product portfolio, a solid infrastructure, a sound financial position, and an exceptional team of employees. I see opportunities to develop the business based upon both current and new products. I am looking forward to contributing my knowledge and leadership skills to grow the business and enhance shareholder value.”
David Phillips, Lead Director, stated, “On behalf of the Board of Directors, I want to thank Jack Kraeutler for his leadership in guiding Meridian Bioscience over the past 25 years. We are very pleased with the appointment of Jack Kenny to the position of CEO at Meridian. The entire Board believes he will continue Meridian’s history of dynamic leadership and company growth and is fully committed to his success.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO.
For more information : http://www.meridianbioscience.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.